• Teladoc Health Reports First Quarter 2024 Results

    Источник: Nasdaq GlobeNewswire / 25 апр 2024 16:05:00   America/New_York

    PURCHASE, NY, April 25, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 (“First Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 (“First Quarter 2023”).

    Financial and Operational Highlights for First Quarter 2024

    • First Quarter 2024 revenue grows 3% year-over-year to $646.1 million
    • First Quarter 2024 net loss of $81.9 million, or $0.49 per share
    • First Quarter 2024 adjusted EBITDA of $63.1 million, up 20% year-over-year

    “We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter,” said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. “During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance.”

    Key Financial Data     
    ($ in thousands, except per share data, unaudited)   
     Three Months Ended  
     March 31,  
      2024   2023  Change
    Revenue$646,131  $629,244  3%
          
    Net loss$(81,889) $(69,228) (18)%
    Net loss per share, basic and diluted$(0.49) $(0.42) (17)%
          
    Adjusted EBITDA (1)$63,140  $52,765  20%

    See note (1) in the Notes section that follows.

    First Quarter 2024

    Revenue increased 3% to $646.1 million from $629.2 million in First Quarter 2023. Access fees revenue grew 1% to $557.2 million and other revenue grew 14% to $89.0 million. U.S. revenue grew 1% to $547.6 million and International revenue grew 13% to $98.5 million.

    Teladoc Health Integrated Care ("Integrated Care") segment revenue increased 8% to $377.1 million in First Quarter 2024 and BetterHelp segment revenue decreased 4% to $269.0 million.

    Net loss totaled $81.9 million, or $0.49 per share, for First Quarter 2024, compared to $69.2 million, or $0.42 per share, for First Quarter 2023. Results for First Quarter 2024 included stock-based compensation expense of $42.3 million, or $0.25 per share, and amortization of acquired intangibles of $64.2 million, or $0.38 per share. The amortization of acquired intangibles increased over the prior year period reflecting a change in the useful lives of certain intangibles in the third quarter of 2023. Net loss for First Quarter 2024 also included $9.7 million, or $0.06 per share, of restructuring costs, primarily related to severance payments.

    Results for First Quarter 2023 primarily included stock-based compensation expense of $46.0 million, or $0.28 per share, and amortization of acquired intangibles of $50.3 million, or $0.31 per share. Net loss for First Quarter 2023 also included $8.1 million, or $0.05 per share, of restructuring costs related to the abandonment of certain excess leased office space.

    Adjusted EBITDA(1) increased 20% to $63.1 million, compared to $52.8 million for First Quarter 2023. Integrated Care segment adjusted EBITDA increased 36% to $47.7 million in First Quarter 2024 and BetterHelp segment adjusted EBITDA decreased 12% to $15.5 million in First Quarter 2024.

    GAAP gross margin, which includes amortization of intangible assets and depreciation of property and equipment, was 65.8% for First Quarter 2024, compared to 67.8% for First Quarter 2023.

    Adjusted gross margin(1) was 69.9% for First Quarter 2024, compared to 69.8% for First Quarter 2023.

    Capex and Cash Flow

    Cash flow from operations was $8.9 million in First Quarter 2024, compared to $13.2 million in First Quarter 2023. Capitalized expenditures and capitalized software development costs (together, “Capex”) was $35.5 million in First Quarter 2024, compared to $45.6 million in First Quarter 2023. Free cash flow was a net outflow of $26.6 million in First Quarter 2024, compared to a net outflow of $32.5 million in First Quarter 2023.

    Financial Outlook

    Teladoc Health provides an outlook based on current market conditions and expectations and what we know today. Accordingly, we believe our outlook ranges provide a reasonable baseline for future financial performance.

    For the second quarter of 2024, we expect:

     2Q 2024 Outlook Range
    Revenue$635 - $660 million
    Adjusted EBITDA$70 - $80 million
    Net loss per share($0.45) - ($0.35)
    U.S. Integrated Care Members (2)92 - 93 million
      
    Integrated Care 
    Revenue growth percentage (year-over-year)2.0% - 5.0%
    Adjusted EBITDA margin12.0% - 14.0%
      
    BetterHelp 
    Revenue growth percentage (year-over-year)(8.0%) - (4.0%)
    Adjusted EBITDA margin9.0% - 10.0%


    For the full year of     2024, we expect:

     Full Year 2024 Outlook Range
    Revenue$2,635 - $2,735 million
    Adjusted EBITDA$350 - $390 million
    Net loss per share($1.10) - ($0.80)
    Free Cash Flow$210 - $240 million
    U.S. Integrated Care Members (2)92 - 94 million
      
    Integrated Care 
    Revenue growth percentage (year-over-year)Low to mid-single digits
    Adjusted EBITDA margin expansion (year-over-year)+150bps to +250bps
      
    BetterHelp 
    Revenue growth percentage (year-over-year)Flat to low single digits
    Adjusted EBITDA margin expansion (year-over-year)Flat +/- 50bps

    See note (2) in the Notes section that follows.

    Three Year Outlook

    We are reiterating the three-year outlook that we disclosed in our earnings release on February 20, 2024.

    Earnings Conference Call

    The First Quarter 2024 earnings conference call and webcast will be held Thursday, April 25, 2024 at 5:00 p.m. E.T. The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 901506. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=60046. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    About Teladoc Health

    Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com. 

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; and (viii) the success of our operational review of the company to achieve a more balanced approach to growth and margin. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

    Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


    TELADOC HEALTH, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (In thousands, except share and per share data, unaudited)
     Three Months Ended
    March 31,
      2024   2023 
    Revenue$646,131  $629,244 
    Expenses:   
    Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) 194,538   190,107 
    Operating expenses:   
    Advertising and marketing 183,329   176,790 
    Sales 54,364   54,490 
    Technology and development 81,388   86,985 
    General and administrative 111,697   114,145 
    Acquisition, integration, and transformation costs 373   5,944 
    Restructuring costs 9,673   8,102 
    Amortization of intangible assets 95,057   66,860 
    Depreciation of property and equipment 2,834   2,923 
    Total expenses 733,253   706,346 
    Loss from operations (87,122)  (77,102)
    Interest income (13,942)  (8,911)
    Interest expense 5,649   5,263 
    Other expense (income), net 370   (4,907)
    Loss before provision for income taxes (79,199)  (68,547)
    Provision for income taxes 2,690   681 
    Net loss$(81,889) $(69,228)
        
    Net loss per share, basic and diluted$(0.49) $(0.42)
        
    Weighted-average shares used to compute basic and diluted net loss per share 167,730,746   162,922,691 


    Stock-based Compensation Summary

    Compensation costs for stock-based awards were classified as follows (in thousands):

     Three Months Ended
    March 31,
     2024 2023
    Cost of revenue (exclusive of depreciation and amortization, which are shown separately)$1,394 $1,353
    Advertising and marketing 3,789  3,126
    Sales 7,967  8,075
    Technology and development 9,299  12,729
    General and administrative 19,876  20,755
    Total stock-based compensation expense (3)$42,325 $46,038

    See note (3) in the Notes section that follows.


    Revenues

     Three Months Ended  
     March 31,  
    ($ in thousands, unaudited)2024 2023 Change
    Revenue by Type     
    Access fees$557,174 $550,870 1%
    Other 88,957  78,374 14%
    Total Revenue$646,131 $629,244 3%
          
    Revenue by Geography     
    U.S. Revenue$547,600 $541,662 1%
    International Revenue 98,531  87,582 13%
    Total Revenue$646,131 $629,244 3%


    Summary Operating Metrics

    Consolidated

     Three Months Ended   
     March 31,   
    (In millions)2024 2023 Change
    Total Visits4.6 4.9 (6)%

    Integrated Care

     As of March 31,  
    (In millions)2024 2023 Change
    U.S. Integrated Care Members (2)91.8 84.9 8%
    Chronic Care Program Enrollment (4)1.121 1.028 9%


     Three Months Ended   
     March 31,   
      2024  2023 Change
    Average Monthly Revenue
    Per U.S. Integrated Care Member (5)    		$1.38 $1.39 (1)%

    BetterHelp

     Average for   
     Three Months Ended   
     March 31,   
    (In millions)2024 2023 Change
    BetterHelp Paying Users (6)0.415 0.467 (11)%

    See notes (2), (4), (5), and (6) in the Notes section that follows.

    Operating Results by Segment (see note (7) in the Notes section that follows)

    The following table presents operating results by reportable segment for the periods indicated:

     Three Months Ended  
     March 31,  
    ($ in thousands, unaudited) 2024   2023  Change
    Teladoc Health Integrated Care     
    Revenue$377,111  $349,972  8%
    Adjusted EBITDA$47,674  $35,127  36%
    Adjusted EBITDA Margin % 12.6%  10.0% 260 bps
          
    BetterHelp     
    Therapy Services$263,712  $275,928  (4)%
    Other Wellness Services 5,308   3,344  59%
    Total Revenue$269,020  $279,272  (4)%
    Adjusted EBITDA$15,466  $17,638  (12)%
    Adjusted EBITDA Margin % 5.7%  6.3% (60) bps



    TELADOC HEALTH, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (In thousands, unaudited)
     Three Months Ended
    March 31,
      2024   2023 
    Cash flows from operating activities:   
    Net loss$(81,889) $(69,228)
    Adjustments to reconcile net loss to net cash flows from operating activities:   
    Amortization of intangible assets 95,057   66,860 
    Depreciation of property and equipment 2,834   2,923 
    Amortization of right-of-use assets 2,614   3,056 
    Provision for allowances for doubtful accounts 86   3,794
    		 
    Stock-based compensation 42,325   46,038 
    Deferred income taxes (1,600)  (355)
    Other, net 1,403   3,244 
    Changes in operating assets and liabilities:   
    Accounts receivable 2,133   (14,046)
    Prepaid expenses and other current assets (23,691)  (6,165)
    Inventory (3,091)  10,000 
    Other assets 1,009   (9,939)
    Accounts payable (5,870)  (9,132)
    Accrued expenses and other current liabilities 25,185   15,452 
    Accrued compensation (51,973)  (32,265)
    Deferred revenue 7,297   5,648 
    Operating lease liabilities (2,861)  (2,858)
    Other liabilities (48)  129 
    Net cash provided by operating activities 8,920   13,156 
    Cash flows from investing activities:   
    Capital expenditures (1,149)  (2,363)
    Capitalized software development costs (34,363)  (43,261)
    Net cash used in investing activities (35,512)  (45,624)
    Cash flows from financing activities:   
    Net proceeds from the exercise of stock options 131   296 
    Proceeds from employee stock purchase plan 1,516   2,731 
    Cash received for withholding taxes on stock-based compensation, net 106   496 
    Other, net (2)  (170)
    Net cash provided by financing activities 1,751   3,353 
    Net decrease in cash and cash equivalents (24,841)  (29,115)
    Effect of foreign currency exchange rate changes (899)  (488)
    Cash and cash equivalents at beginning of the period 1,123,675   918,182 
    Cash and cash equivalents at end of the period$1,097,935  $888,579 



    CONDENSED CONSOLIDATED BALANCE SHEETS
    (In thousands, except share and per share data, unaudited)
     March 31,
    2024    		 December 31,
    2023
    Assets   
    Current assets:   
    Cash and cash equivalents$1,097,935  $1,123,675 
    Accounts receivable, net of allowance for doubtful accounts of $3,530 and $4,240 at March 31, 2024 and December 31, 2023, respectively 214,293   217,423 
    Inventories 32,268   29,513 
    Prepaid expenses and other current assets 141,769   118,437 
    Total current assets 1,486,265   1,489,048 
    Property and equipment, net 29,550   32,032 
    Goodwill 1,073,190   1,073,190 
    Intangible assets, net 1,614,238   1,677,781 
    Operating lease - right-of-use assets 37,506   40,060 
    Other assets 80,007   80,258 
    Total assets$4,320,756  $4,392,369 
    Liabilities and stockholders’ equity   
    Current liabilities:   
    Accounts payable$37,674  $43,637 
    Accrued expenses and other current liabilities 199,418   178,634 
    Accrued compensation 50,523   102,686 
    Deferred revenue-current 101,229   95,659 
    Total current liabilities 388,844   420,616 
    Other liabilities 1,023   1,080 
    Operating lease liabilities, net of current portion 39,971   42,837 
    Deferred revenue, net of current portion 15,002   13,623 
    Deferred taxes, net 47,472   49,452 
    Convertible senior notes, net 1,539,546   1,538,688 
    Commitments and contingencies   
    Stockholders’ equity:   
    Common stock, $0.001 par value; 300,000,000 shares authorized; 169,314,029 shares and 166,658,253 shares issued and outstanding as of March 31, 2024 and December 31, 2023 respectively 169   167 
    Additional paid-in capital 17,637,902   17,591,551 
    Accumulated deficit (15,310,544)  (15,228,655)
    Accumulated other comprehensive loss (38,629)  (36,990)
    Total stockholders’ equity 2,288,898   2,326,073 
    Total liabilities and stockholders’ equity$4,320,756  $4,392,369 


    Non-GAAP Financial Measures:

    To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we use non-GAAP financial measures to clarify and enhance an understanding of past performance, which include adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA, and free cash flow. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance, and are commonly used by investors to evaluate our performance and that of our competitors. We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows. We use these non-GAAP financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.

    Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which are shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue.

    EBITDA consists of net loss before interest income; interest expense; other expense (income), net, including foreign currency exchange gains or losses; provision for income taxes; amortization of intangible assets; and depreciation of property and equipment. Adjusted EBITDA consists of net loss before interest income; interest expense; other expense (income), net, including foreign currency exchange gains or losses; provision for income taxes; amortization of intangible assets; depreciation of property and equipment; stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs.

    Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.

    Our use of these non-GAAP terms may vary from that of others in our industry, and other companies may calculate such measures differently than we do, limiting their usefulness as comparative measures.

    Non-GAAP measures have important limitations as analytical tools and you should not consider them in isolation, and they should not be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other measures derived in accordance with GAAP. Some of these limitations are:

    • adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;
    • adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;
    • EBITDA and adjusted EBITDA eliminate the impact of the provision for income taxes on our results of operations, and they do not reflect interest income, interest expense or other expense (income), net;
    • adjusted EBITDA does not reflect restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;
    • adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration, and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management (CRM) and enterprise resource planning (ERP) systems. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but, rather, incremental costs incurred in connection with our acquisition and integration activities; and
    • adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.

    In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements.

    We compensate for these limitations by using these non-GAAP measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.

    In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

    The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively:


    Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin
    (In thousands, unaudited)
     Three Months Ended
    March 31,
      2024   2023 
    Revenue$646,131  $629,244 
    Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) (194,538)  (190,107)
    Amortization of intangible assets and depreciation of property and equipment (26,312)  (12,531)
    Gross profit 425,281   426,606 
    Amortization of intangible assets and depreciation of property and equipment 26,312   12,531 
    Adjusted gross profit$451,593  $439,137 
        
    Gross margin 65.8%  67.8%
    Adjusted gross margin 69.9%  69.8%


    The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to EBITDA and adjusted EBITDA:

    Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA
    (In thousands, except for outlook data, unaudited)
         Outlook in millions (8)
     Three Months Ended
    March 31,    		 Second Quarter Full Year
      2024   2023  2024 2024
    Net loss$(81,889) $(69,228) $(77) - (60) $(185) - (134)
    Add:       
    Interest income (13,942)  (8,911)    
    Interest expense 5,649   5,263     
    Other expense (income), net 370   (4,907)    
    Provision for income taxes 2,690   681     
    Amortization of intangible assets 95,057   66,860     
    Depreciation of property and equipment 2,834   2,923     
    Total Adjustments 92,658   61,909     
    Consolidated EBITDA 10,769   (7,319)    
    Adjustments:       
    Stock-based compensation 42,325   46,038     
    Acquisition, integration, and transformation costs 373   5,944     
    Restructuring costs 9,673   8,102     
    Total Adjustments 52,371   60,084  130 - 157 484 - 575
    Consolidated Adjusted EBITDA$63,140  $52,765  $70 - 80 $350 - 390
            
    Segment Adjusted EBITDA       
    Teladoc Health Integrated Care$47,674  $35,127     
    BetterHelp 15,466   17,638     
    Consolidated Adjusted EBITDA$63,140  $52,765     

    See note (8) in the Notes section that follows.


    The following is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow:


    Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow
    (In thousands, unaudited)
     Three Months Ended Outlook (9)
     March 31, Full Year
      2024   2023  2024 (in millions)
    Net cash provided by operating activities$8,920  $13,156  $354 - 374
    Capital expenditures (1,149)  (2,363)  
    Capitalized software development costs (34,363)  (43,261)  
    Capex (35,512)  (45,624) (144) - (134)
    Free cash flow$(26,592) $(32,468) $210 - 240

    See note (9) in the Notes section that follows.

    Notes:

    1. A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these non-GAAP measures is also included under the heading “Non-GAAP Financial Measures.”

    2. U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.

    3. Excluding the amount capitalized related to software development projects.

    4. Chronic Care Program Enrollment represents the total number of enrollees across our suite of chronic care programs at the end of a given period.

    5. Average monthly revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 2) during the applicable period.

    6. BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy services during the applicable period.

    7. We have two segments: Teladoc Health Integrated Care (“Integrated Care”) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis.

    8. We have not provided a full line-item reconciliation for net loss to adjusted EBITDA outlook because we do not provide outlook on the individual reconciling items between net loss and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as impairments, stock-based compensation and the related tax impact, provision for income taxes, acquisition, integration, and transformation costs, and restructuring costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure outlook is not available without unreasonable effort.

    9. We have not provided a line-item reconciliation for free cash flow to net cash from operating activities for this future period because we believe such a reconciliation would imply a degree of precision and certainty that could be confusing to investors and we are unable to reasonably predict certain items contained in the GAAP measure without unreasonable efforts.

    Investors:
    617-444-9612
    ir@teladochealth.com

    Media:
    Chris Stenrud
    860-491-8821
    pr@teladochealth.com


    Primary Logo

Опубликовать